{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:19:54Z","timestamp":1792131594344,"version":"4.4.0"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T00:00:00Z","timestamp":1756598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Science and Technology Plan Project","award":["CJ20245037"],"award-info":[{"award-number":["CJ20245037"]}]},{"name":"the Young Talent Development Plan of Changzhou Health Commission","award":["CZQM2023022"],"award-info":[{"award-number":["CZQM2023022"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01844-3","type":"journal-article","created":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T06:34:10Z","timestamp":1756622050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Identification and validation of prognostic genes associated with mitochondrial nuclear genes in gastric cancer"],"prefix":"10.1007","volume":"25","author":[{"given":"Cong","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6528-3536","authenticated-orcid":false,"given":"Xiaoyue","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9492-3002","authenticated-orcid":false,"given":"Tong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2975-5883","authenticated-orcid":false,"given":"Yanzhi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,31]]},"reference":[{"key":"1844_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1844_CR2","first-page":"23","volume":"27","author":"CG Zorlu","year":"1995","unstructured":"Zorlu CG, Cobanoglu O, Ekici E, et al. Preoperative assessment of myometrial invasion of endometrial carcinoma by transvaginal ultrasonography. Mater Med Pol. 1995;27:23\u20135.","journal-title":"Mater Med Pol"},{"key":"1844_CR3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat Rev Clin Oncol. 2023;20:338\u201349.","journal-title":"Nat Rev Clin Oncol"},{"key":"1844_CR4","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2018.883","volume":"12","author":"M Casamayor","year":"2018","unstructured":"Casamayor M, Morlock R, Maeda H, Ajani J. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12: 883.","journal-title":"Ecancermedicalscience"},{"key":"1844_CR5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110794","volume":"109","author":"LD Popov","year":"2023","unstructured":"Popov LD. Mitochondria as intracellular signalling organelles. An update. Cell Signal. 2023;109: 110794.","journal-title":"Cell Signal"},{"key":"1844_CR6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.tibs.2017.02.003","volume":"42","author":"SF Pearce","year":"2017","unstructured":"Pearce SF, Rebelo-Guiomar P, D\u2019Souza AR, et al. Regulation of mammalian mitochondrial gene expression: recent advances. Trends Biochem Sci. 2017;42:625\u201339.","journal-title":"Trends Biochem Sci"},{"key":"1844_CR7","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41580-018-0092-0","volume":"20","author":"N Pfanner","year":"2019","unstructured":"Pfanner N, Warscheid B, Wiedemann N. Mitochondrial proteins: from biogenesis to functional networks. Nat Rev Mol Cell Biol. 2019;20:267\u201384.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1844_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12040782","author":"I San-Millan","year":"2023","unstructured":"San-Millan I. The key role of mitochondrial function in health and disease. Antioxidants (Basel). 2023. https:\/\/doi.org\/10.3390\/antiox12040782.","journal-title":"Antioxidants (Basel)"},{"key":"1844_CR9","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.mito.2020.04.012","volume":"53","author":"H Li","year":"2020","unstructured":"Li H, Slone J, Huang T. The role of mitochondrial-related nuclear genes in age-related common disease. Mitochondrion. 2020;53:38\u201347.","journal-title":"Mitochondrion"},{"key":"1844_CR10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41580-019-0173-8","volume":"21","author":"FJ Bock","year":"2020","unstructured":"Bock FJ, Tait SWG. Mitochondria as multifaceted regulators of cell death. Nat Rev Mol Cell Biol. 2020;21:85\u2013100.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1844_CR11","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/1535370216641787","volume":"241","author":"CC Hsu","year":"2016","unstructured":"Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med (Maywood). 2016;241:1281\u201395.","journal-title":"Exp Biol Med (Maywood)"},{"key":"1844_CR12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41588-019-0557-x","volume":"52","author":"Y Yuan","year":"2020","unstructured":"Yuan Y, Ju YS, Kim Y, et al. Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet. 2020;52:342\u201352.","journal-title":"Nat Genet"},{"key":"1844_CR13","first-page":"153303382412585","volume":"23","author":"L Lv","year":"2024","unstructured":"Lv L, Huang Y, Li Q, Wu Y, Zheng L. A comprehensive prognostic model for colon adenocarcinoma depending on nuclear-mitochondrial-related genes. Technol Cancer Res Treat. 2024;23:15330338241258570.","journal-title":"Technol Cancer Res Treat"},{"key":"1844_CR14","volume":"9","author":"X Zhang","year":"2021","unstructured":"Zhang X, Dong W, Zhang J, et al. A novel mitochondrial-related nuclear gene signature predicts overall survival of lung adenocarcinoma patients. Front Cell Dev Biol. 2021;9: 740487.","journal-title":"Front Cell Dev Biol"},{"key":"1844_CR15","volume":"11","author":"X Jiang","year":"2021","unstructured":"Jiang X, Xia Y, Meng H, et al. Identification of a nuclear mitochondrial-related multi-genes signature to predict the prognosis of bladder cancer. Front Oncol. 2021;11: 746029.","journal-title":"Front Oncol"},{"key":"1844_CR16","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.31557\/APJCP.2021.22.6.1799","volume":"22","author":"C Meneur","year":"2021","unstructured":"Meneur C, Eswaran S, Adiga D, et al. Analysis of nuclear encoded mitochondrial gene networks in cervical cancer. Asian Pac J Cancer Prev. 2021;22:1799\u2013811.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1844_CR17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10495-022-01709-0","volume":"27","author":"P Tanprasert","year":"2022","unstructured":"Tanprasert P, Limpakan Yamada S, Chattipakorn SC, Chattipakorn N, Shinlapawittayatorn K. Targeting mitochondria as a therapeutic anti-gastric cancer approach. Apoptosis. 2022;27:163\u201383.","journal-title":"Apoptosis"},{"key":"1844_CR18","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43: e47.","journal-title":"Nucleic Acids Res"},{"key":"1844_CR19","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"1844_CR20","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, et al. ClusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation (Camb). 2021;2: 100141.","journal-title":"Innovation (Camb)"},{"key":"1844_CR21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s12986-024-00864-2","volume":"21","author":"X Chen","year":"2024","unstructured":"Chen X, Zhao Y, Sun J, Jiang Y, Tang Y. Identification of metabolic syndrome using lipid accumulation product and cardiometabolic index based on NHANES data from 2005 to 2018. Nutr Metab (Lond). 2024;21:96.","journal-title":"Nutr Metab (Lond)"},{"key":"1844_CR22","first-page":"892","volume":"54","author":"R Chen","year":"2023","unstructured":"Chen R, Wang J, Wang S, Tang S, Suo C. Construction of a risk prediction model for lung cancer based on lifestyle behaviors in the UK Biobank large-scale population cohort. Sichuan Da Xue Xue Bao Yi Xue Ban. 2023;54:892\u20138.","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"1844_CR23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4097\/kja.19183","volume":"72","author":"J In","year":"2019","unstructured":"In J, Lee DK. Survival analysis: part II - applied clinical data analysis. Korean J Anesthesiol. 2019;72:441\u201357.","journal-title":"Korean J Anesthesiol"},{"key":"1844_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"J Friedman","year":"2010","unstructured":"Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1\u201322.","journal-title":"J Stat Softw"},{"key":"1844_CR25","volume":"9","author":"TT Liu","year":"2021","unstructured":"Liu TT, Li R, Huo C, et al. Identification of CDK2-related immune forecast model and ceRNA in lung adenocarcinoma, a pan-cancer analysis. Front Cell Dev Biol. 2021;9: 682002.","journal-title":"Front Cell Dev Biol"},{"key":"1844_CR26","doi-asserted-by":"crossref","first-page":"15059","DOI":"10.1038\/s41598-023-42053-w","volume":"13","author":"Z Lin","year":"2023","unstructured":"Lin Z, He Y, Wu Z, et al. Comprehensive analysis of copper-metabolism-related genes about prognosis and immune microenvironment in osteosarcoma. Sci Rep. 2023;13:15059.","journal-title":"Sci Rep"},{"key":"1844_CR27","volume":"13","author":"J Qing","year":"2022","unstructured":"Qing J, Li C, Hu X, et al. Differentiation of T helper 17 cells may mediate the abnormal humoral immunity in IgA nephropathy and inflammatory bowel disease based on shared genetic effects. Front Immunol. 2022;13: 916934.","journal-title":"Front Immunol"},{"key":"1844_CR28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.","journal-title":"BMC Bioinformatics"},{"key":"1844_CR29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/978-1-0716-0327-7_16","volume":"2120","author":"G Sturm","year":"2020","unstructured":"Sturm G, Finotello F, List M. Immunedeconv: an R package for unified access to computational methods for estimating immune cell fractions from bulk RNA-sequencing data. Methods Mol Biol. 2020;2120:223\u201332.","journal-title":"Methods Mol Biol"},{"key":"1844_CR30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28:1747\u201356.","journal-title":"Genome Res"},{"key":"1844_CR31","volume":"10","author":"P Hu","year":"2024","unstructured":"Hu P, Li B, Yin Z, et al. Multi-omics characterization of macrophage polarization-related features in osteoarthritis based on a machine learning computational framework. Heliyon. 2024;10: e30335.","journal-title":"Heliyon"},{"key":"1844_CR32","volume":"13","author":"W Wang","year":"2022","unstructured":"Wang W, Lu Z, Wang M, et al. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma. Front Immunol. 2022;13: 998236.","journal-title":"Front Immunol"},{"key":"1844_CR33","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.2337\/dc20-0028","volume":"43","author":"F Cheng","year":"2020","unstructured":"Cheng F, Luk AO, Tam CHT, et al. Shortened relative leukocyte telomere length is associated with prevalent and incident cardiovascular complications in type 2 diabetes: analysis from the Hong Kong Diabetes Register. Diabetes Care. 2020;43:2257\u201365.","journal-title":"Diabetes Care"},{"key":"1844_CR34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","volume":"396","author":"EC Smyth","year":"2020","unstructured":"Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396:635\u201348.","journal-title":"Lancet"},{"key":"1844_CR35","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/1055-9965.EPI-13-1057","volume":"23","author":"P Karimi","year":"2014","unstructured":"Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700\u201313.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1844_CR36","doi-asserted-by":"crossref","first-page":"101042831771462","DOI":"10.1177\/1010428317714626","volume":"39","author":"Z Song","year":"2017","unstructured":"Song Z, Wu Y, Yang J, Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39:1010428317714626.","journal-title":"Tumour Biol"},{"key":"1844_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/cdd.2012.81","volume":"20","author":"G Ashrafi","year":"2013","unstructured":"Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell Death Differ. 2013;20:31\u201342.","journal-title":"Cell Death Differ"},{"key":"1844_CR38","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41420-023-01752-z","volume":"9","author":"YY Lu","year":"2023","unstructured":"Lu YY, Zhu CY, Ding YX, et al. Cepharanthine, a regulator of keap1-Nrf2, inhibits gastric cancer growth through oxidative stress and energy metabolism pathway. Cell Death Discov. 2023;9:450.","journal-title":"Cell Death Discov"},{"key":"1844_CR39","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.3748\/wjg.v20.i14.3950","volume":"20","author":"HC Lee","year":"2014","unstructured":"Lee HC, Huang KH, Yeh TS, Chi CW. Somatic alterations in mitochondrial DNA and mitochondrial dysfunction in gastric cancer progression. World J Gastroenterol. 2014;20:3950\u20139.","journal-title":"World J Gastroenterol"},{"key":"1844_CR40","first-page":"241","volume":"38","author":"K Ohara","year":"2017","unstructured":"Ohara K, Arai E, Takahashi Y, et al. Genes involved in development and differentiation are commonly methylated in cancers derived from multiple organs: a single-institutional methylome analysis using 1007 tissue specimens. Carcinogenesis. 2017;38:241\u201351.","journal-title":"Carcinogenesis"},{"key":"1844_CR41","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1080\/21655979.2022.2037368","volume":"13","author":"H Tian","year":"2022","unstructured":"Tian H, Yan H, Zhang Y, et al. Knockdown of mitochondrial threonyl-tRNA synthetase 2 inhibits lung adenocarcinoma cell proliferation and induces apoptosis. Bioengineered. 2022;13:5190\u2013204.","journal-title":"Bioengineered"},{"key":"1844_CR42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/03936155231212925","volume":"39","author":"L Suo","year":"2024","unstructured":"Suo L, Liang X, Zhang W, et al. Potential prognostic biomarkers of hepatocellular carcinoma based on 4D label-free quantitative proteomics analysis pilot investigation. Int J Biol Markers. 2024;39:59\u201369.","journal-title":"Int J Biol Markers"},{"key":"1844_CR43","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002467","author":"D Zeng","year":"2021","unstructured":"Zeng D, Wu J, Luo H, et al. Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002467.","journal-title":"J Immunother Cancer"},{"key":"1844_CR44","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fimmu.2020.01280","volume":"11","author":"L Walcher","year":"2020","unstructured":"Walcher L, Kistenmacher AK, Suo H, et al. Cancer stem cells-origins and biomarkers: perspectives for targeted personalized therapies. Front Immunol. 2020;11:1280.","journal-title":"Front Immunol"},{"key":"1844_CR45","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10120-020-01090-4","volume":"23","author":"K Kono","year":"2020","unstructured":"Kono K, Nakajima S, Mimura K. Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020;23:565\u201378.","journal-title":"Gastric Cancer"},{"key":"1844_CR46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41:374\u2013403.","journal-title":"Cancer Cell"},{"key":"1844_CR47","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","volume":"7","author":"D Zeng","year":"2019","unstructured":"Zeng D, Li M, Zhou R, et al. Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures. Cancer Immunol Res. 2019;7:737\u201350.","journal-title":"Cancer Immunol Res"},{"key":"1844_CR48","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41419-022-05320-8","volume":"13","author":"H Sun","year":"2022","unstructured":"Sun H, Wang X, Wang X, Xu M, Sheng W. The role of cancer-associated fibroblasts in tumorigenesis of gastric cancer. Cell Death Dis. 2022;13:874.","journal-title":"Cell Death Dis"},{"key":"1844_CR49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.3892\/ol.2018.8296","volume":"15","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Peng C. Cancer-associated fibroblasts regulate the biological behavior of cancer cells and stroma in gastric cancer. Oncol Lett. 2018;15:691\u20138.","journal-title":"Oncol Lett"},{"key":"1844_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21072606","author":"O Ciesielski","year":"2020","unstructured":"Ciesielski O, Biesiekierska M, Panthu B, et al. The epigenetic profile of tumor endothelial cells. Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21072606.","journal-title":"Int J Mol Sci"},{"key":"1844_CR51","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13059-022-02828-2","volume":"23","author":"B Kang","year":"2022","unstructured":"Kang B, Camps J, Fan B, et al. Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. Genome Biol. 2022;23:265.","journal-title":"Genome Biol"},{"key":"1844_CR52","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.7150\/thno.71833","volume":"12","author":"Y Li","year":"2022","unstructured":"Li Y, Hu X, Lin R, et al. Single-cell landscape reveals active cell subtypes and their interaction in the tumor microenvironment of gastric cancer. Theranostics. 2022;12:3818\u201333.","journal-title":"Theranostics"},{"key":"1844_CR53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.","journal-title":"Mol Cancer"},{"key":"1844_CR54","first-page":"451","volume":"21","author":"X Kong","year":"2024","unstructured":"Kong X, Zhang J, Chen S, et al. Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med. 2024;21:451\u201372.","journal-title":"Cancer Biol Med"},{"key":"1844_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910719","author":"N Bolandi","year":"2021","unstructured":"Bolandi N, Derakhshani A, Hemmat N, et al. The positive and negative immunoregulatory role of B7 family: promising novel targets in gastric cancer treatment. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms221910719.","journal-title":"Int J Mol Sci"},{"key":"1844_CR56","first-page":"264","volume":"71","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Badgwell BD. Current treatment and recent progress in gastric cancer. CA Cancer J Clin. 2021;71:264\u201379.","journal-title":"CA Cancer J Clin"},{"key":"1844_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082273","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu P, Xu L, et al. Current progress on predictive biomarkers for response to immune checkpoint inhibitors in gastric cancer: how to maximize the immunotherapeutic benefit? Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15082273.","journal-title":"Cancers (Basel)"},{"key":"1844_CR58","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3390\/cancers14041054","volume":"14","author":"S Takei","year":"2022","unstructured":"Takei S, Kawazoe A, Shitara K. The new era of immunotherapy in gastric cancer. Cancers (Basel). 2022;14:1054.","journal-title":"Cancers (Basel)."},{"key":"1844_CR59","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/nrm2858","volume":"11","author":"S Negrini","year":"2010","unstructured":"Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability\u2013an evolving hallmark of cancer. Nat Rev Mol Cell Biol. 2010;11:220\u20138.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Suppl 7","key":"1844_CR60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/annonc\/mdl960","volume":"17","author":"L Ottini","year":"2006","unstructured":"Ottini L, Falchetti M, Lupi R, et al. Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol. 2006;17(Suppl 7):97\u2013102.","journal-title":"Ann Oncol"},{"key":"1844_CR61","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1002\/ijc.22833","volume":"121","author":"Y Zhou","year":"2007","unstructured":"Zhou Y, Li N, Zhuang W, et al. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer. 2007;121:1481\u20136.","journal-title":"Int J Cancer"},{"key":"1844_CR62","doi-asserted-by":"crossref","first-page":"832","DOI":"10.4161\/cbt.6.6.4196","volume":"6","author":"M Katoh","year":"2007","unstructured":"Katoh M. Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change and genetic alteration in gastric cancer. Cancer Biol Ther. 2007;6:832\u20139.","journal-title":"Cancer Biol Ther"},{"key":"1844_CR63","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.2217\/fon-2016-0224","volume":"12","author":"J Jiang","year":"2016","unstructured":"Jiang J, Jia ZF, Cao DH, et al. Association of the miR-146a rs2910164 polymorphism with gastric cancer susceptibility and prognosis. Future Oncol. 2016;12:2215\u201326.","journal-title":"Future Oncol"},{"key":"1844_CR64","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/gtmb.2019.0140","volume":"24","author":"Y Li","year":"2020","unstructured":"Li Y, Zhang Z, Yang Y, Ma J. Long noncoding RNA HOX transcript antisense RNA gene rs17720428 single nucleotide polymorphism is associated with gastric cancer risk and prognosis. Genet Test Mol Biomarkers. 2020;24:38\u201346.","journal-title":"Genet Test Mol Biomarkers"},{"key":"1844_CR65","volume":"10","author":"C Wang","year":"2015","unstructured":"Wang C, Jia Z, Cao D, et al. Polymorphism of DNA methyltransferase 3b and association with development and prognosis in gastric cancer. PLoS ONE. 2015;10: e0134059.","journal-title":"PLoS ONE"},{"key":"1844_CR66","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12876-020-01299-8","volume":"20","author":"J Behroozi","year":"2020","unstructured":"Behroozi J, Shahbazi S, Bakhtiarizadeh MR, Mahmoodzadeh H. ADAR expression and copy number variation in patients with advanced gastric cancer. BMC Gastroenterol. 2020;20:152.","journal-title":"BMC Gastroenterol"},{"key":"1844_CR67","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/onc.2015.209","volume":"35","author":"L Liang","year":"2016","unstructured":"Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene. 2016;35:1475\u201382.","journal-title":"Oncogene"},{"key":"1844_CR68","volume":"124","author":"L Ke","year":"2023","unstructured":"Ke L, Li S, Huang D. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Int Immunopharmacol. 2023;124: 110986.","journal-title":"Int Immunopharmacol"},{"key":"1844_CR69","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"1844_CR70","volume":"20","author":"J Cao","year":"2022","unstructured":"Cao J, Yang X, Chen S, et al. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: a meta-analysis and bioinformatics analysis. Transl Oncol. 2022;20: 101375.","journal-title":"Transl Oncol"},{"key":"1844_CR71","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1001\/jamaoncol.2019.0626","volume":"5","author":"A Addeo","year":"2019","unstructured":"Addeo A, Banna GL, Weiss GJ. Tumor mutation burden-from hopes to doubts. JAMA Oncol. 2019;5:934\u20135.","journal-title":"JAMA Oncol"},{"key":"1844_CR72","volume":"12","author":"MA Wood","year":"2020","unstructured":"Wood MA, Weeder BR, David JK, Nellore A, Thompson RF. Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival. Genome Med. 2020;12: 33.","journal-title":"Genome Med"},{"key":"1844_CR73","doi-asserted-by":"crossref","first-page":"a035204","DOI":"10.1101\/cshperspect.a035204","volume":"11","author":"SJ Roberts-Thomson","year":"2019","unstructured":"Roberts-Thomson SJ, Chalmers SB, Monteith GR. The calcium-signaling toolkit in cancer: remodeling and targeting. Cold Spring Harb Perspect Biol. 2019;11:a035204.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1844_CR74","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrc.2017.18","volume":"17","author":"GR Monteith","year":"2017","unstructured":"Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium-cancer signalling nexus. Nat Rev Cancer. 2017;17:367\u201380.","journal-title":"Nat Rev Cancer"},{"key":"1844_CR75","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/bph.14195","volume":"176","author":"JF Hastings","year":"2019","unstructured":"Hastings JF, Skhinas JN, Fey D, Croucher DR, Cox TR. The extracellular matrix as a key regulator of intracellular signalling networks. Br J Pharmacol. 2019;176:82\u201392.","journal-title":"Br J Pharmacol"},{"key":"1844_CR76","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","volume":"11","author":"J Winkler","year":"2020","unstructured":"Winkler J, Abisoye-Ogunniyan A, Metcalf KJ, Werb Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat Commun. 2020;11:5120.","journal-title":"Nat Commun"},{"key":"1844_CR77","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.semcancer.2019.09.004","volume":"62","author":"V Mohan","year":"2020","unstructured":"Mohan V, Das A, Sagi I. Emerging roles of ECM remodeling processes in cancer. Semin Cancer Biol. 2020;62:192\u2013200.","journal-title":"Semin Cancer Biol"},{"key":"1844_CR78","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.15252\/embr.201439246","volume":"15","author":"MW Pickup","year":"2014","unstructured":"Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014;15:1243\u201353.","journal-title":"EMBO Rep"},{"key":"1844_CR79","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/cells9020394","volume":"9","author":"AM Moreira","year":"2020","unstructured":"Moreira AM, Pereira J, Melo S, et al. The extracellular matrix: an accomplice in gastric cancer development and progression. Cells. 2020;9:394.","journal-title":"Cells"},{"key":"1844_CR80","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10120-021-01259-5","volume":"25","author":"T Zhang","year":"2022","unstructured":"Zhang T, Li X, He Y, et al. Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer. Gastric Cancer. 2022;25:346\u201359.","journal-title":"Gastric Cancer"},{"key":"1844_CR81","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.matbio.2020.05.001","volume":"91\u201392","author":"M Yamauchi","year":"2020","unstructured":"Yamauchi M, Gibbons DL, Zong C, et al. Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. Matrix Biol. 2020;91\u201392:8\u201318.","journal-title":"Matrix Biol"},{"key":"1844_CR82","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153780","volume":"231","author":"S Kadkhoda","year":"2022","unstructured":"Kadkhoda S, Ghafouri-Fard S. Function of miRNA-145-5p in the pathogenesis of human disorders. Pathol Res Pract. 2022;231: 153780.","journal-title":"Pathol Res Pract"},{"key":"1844_CR83","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15430\/JCP.2017.22.1.33","volume":"22","author":"JW Lee","year":"2017","unstructured":"Lee JW, Kim N, Park JH, et al. Differential microRNA expression between gastric cancer tissue and non-cancerous gastric mucosa according to Helicobacter pylori status. J Cancer Prev. 2017;22:33\u20139.","journal-title":"J Cancer Prev"},{"key":"1844_CR84","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1186\/s12935-020-01483-6","volume":"20","author":"K Zhou","year":"2020","unstructured":"Zhou K, Song B, Wei M, Fang J, Xu Y. MiR-145-5p suppresses the proliferation, migration and invasion of gastric cancer epithelial cells via the ANGPT2\/NOD_LIKE_RECEPTOR axis. Cancer Cell Int. 2020;20:416.","journal-title":"Cancer Cell Int"},{"key":"1844_CR85","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s10120-019-01018-7","volume":"23","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Wang C, Zhang Y, et al. Circdusp16 promotes the tumorigenesis and invasion of gastric cancer by sponging miR-145-5p. Gastric Cancer. 2020;23:437\u201348.","journal-title":"Gastric Cancer"},{"key":"1844_CR86","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12871-020-01179-4","volume":"20","author":"C Ju","year":"2020","unstructured":"Ju C, Zhou J, Miao H, Chen X, Zhang Q. Bupivacaine suppresses the progression of gastric cancer through regulating circ_0000376\/miR-145-5p axis. BMC Anesthesiol. 2020;20:275.","journal-title":"BMC Anesthesiol"},{"key":"1844_CR87","first-page":"27764","volume":"14","author":"F Bilan","year":"2024","unstructured":"Bilan F, Amini M, Doustvandi MA, et al. Simultaneous suppression of miR-21 and restoration of miR-145 in gastric cancer cells; a promising strategy for inhibition of cell proliferation and migration. Bioimpacts. 2024;14:27764.","journal-title":"Bioimpacts"},{"key":"1844_CR88","first-page":"3026","volume":"20","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Wen X, Hu XL, et al. Downregulation of miR-145-5p correlates with poor prognosis in gastric cancer. Eur Rev Med Pharmacol Sci. 2016;20:3026\u201330.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1844_CR89","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/1759-7714.14408","volume":"13","author":"H Zhang","year":"2022","unstructured":"Zhang H, Huang T, Yuan S, et al. Circ_0020123 plays an oncogenic role in non-small cell lung cancer depending on the regulation of miR-512-3p\/CORO1C. Thorac Cancer. 2022;13:1406\u201318.","journal-title":"Thorac Cancer"},{"key":"1844_CR90","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/21655979.2021.1882164","volume":"12","author":"Z Shi","year":"2021","unstructured":"Shi Z, Shen C, Yu C, et al. Long non-coding RNA LINC00997 silencing inhibits the progression and metastasis of colorectal cancer by sponging miR-512-3p. Bioengineered. 2021;12:627\u201339.","journal-title":"Bioengineered"},{"key":"1844_CR91","volume":"726","author":"K Wang","year":"2020","unstructured":"Wang K, Sun H, Sun T, et al. Long non-coding RNA AFAP1-AS1 promotes proliferation and invasion in prostate cancer via targeting miR-512-3p. Gene. 2020;726: 144169.","journal-title":"Gene"},{"key":"1844_CR92","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4149\/neo_2019_190106N18","volume":"67","author":"WJ Duan","year":"2020","unstructured":"Duan WJ, Bi PD, Ma Y, Liu NQ, Zhen X. MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin. Neoplasma. 2020;67:102\u201310.","journal-title":"Neoplasma"},{"key":"1844_CR93","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ajur.2024.01.007","volume":"11","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Wang Z, Li H, et al. LncRNA HCG18 promotes prostate cancer progression by regulating the miR-512-3p\/HK-2 axis. Asian J Urol. 2024;11:575\u201385.","journal-title":"Asian J Urol"},{"key":"1844_CR94","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155281","volume":"257","author":"Y Chen","year":"2024","unstructured":"Chen Y, Chen L, Wu J, Su D. Hsa_circ_0087862 contributes to the progression of colorectal cancer through regulating miR-512-3p\/HK2 axis. Pathol Res Pract. 2024;257: 155281.","journal-title":"Pathol Res Pract"},{"key":"1844_CR95","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-020-05937-3","volume":"185","author":"Z Mohamadzade","year":"2021","unstructured":"Mohamadzade Z, Mahjoubi F, Soltani BM. Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer. Breast Cancer Res Treat. 2021;185:95\u2013106.","journal-title":"Breast Cancer Res Treat"},{"key":"1844_CR96","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s12935-020-01547-7","volume":"20","author":"D Dou","year":"2020","unstructured":"Dou D, Ren X, Han M, et al. Circube2d2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p\/CDCA3 axis. Cancer Cell Int. 2020;20:454.","journal-title":"Cancer Cell Int"},{"key":"1844_CR97","volume":"26","author":"M Kong","year":"2020","unstructured":"Kong M, Han Y, Zhao Y, Zhang H. MiR-512-3p overcomes resistance to cisplatin in retinoblastoma by promoting apoptosis induced by endoplasmic reticulum stress. Med Sci Monit. 2020;26: e923817.","journal-title":"Med Sci Monit"},{"key":"1844_CR98","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1089\/dna.2021.0059","volume":"40","author":"H Yang","year":"2021","unstructured":"Yang H, Zhang X, Zhu L, Yang Y, Yin X. YY1-induced lncRNA PART1 enhanced resistance of ovarian cancer cells to cisplatin by regulating miR-512-3p\/CHRAC1 axis. DNA Cell Biol. 2021;40:821\u201332.","journal-title":"DNA Cell Biol"},{"key":"1844_CR99","doi-asserted-by":"publisher","DOI":"10.3390\/cells11172673","author":"P de la Cruz-Ojeda","year":"2022","unstructured":"de la Cruz-Ojeda P, Schmid T, Boix L, et al. MiR-200c-3p, miR-222-5p, and miR-512-3p constitute a biomarker signature of sorafenib effectiveness in advanced hepatocellular carcinoma. Cells. 2022. https:\/\/doi.org\/10.3390\/cells11172673.","journal-title":"Cells"},{"key":"1844_CR100","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1158\/1535-7163.MCT-09-0499","volume":"8","author":"JM Carboni","year":"2009","unstructured":"Carboni JM, Wittman M, Yang Z, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R\/IR. Mol Cancer Ther. 2009;8:3341\u20139.","journal-title":"Mol Cancer Ther"},{"key":"1844_CR101","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2010-0032","volume":"151","author":"JE Dinchuk","year":"2010","unstructured":"Dinchuk JE, Cao C, Huang F, et al. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR\/IR inhibitor, BMS-754807. Endocrinology. 2010;151:4123\u201332.","journal-title":"Endocrinology"},{"key":"1844_CR102","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s10637-023-01360-9","volume":"41","author":"C Zhang","year":"2023","unstructured":"Zhang C, Zhao X, Wang Z, et al. Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase. Invest New Drugs. 2023;41:438\u201352.","journal-title":"Invest New Drugs"},{"key":"1844_CR103","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13104-016-1919-4","volume":"9","author":"SE Franks","year":"2016","unstructured":"Franks SE, Jones RA, Briah R, Murray P, Moorehead RA. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. BMC Res Notes. 2016;9:134.","journal-title":"BMC Res Notes"},{"key":"1844_CR104","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.3390\/cancers12123717","volume":"12","author":"M Fuentes-Baile","year":"2020","unstructured":"Fuentes-Baile M, Ventero MP, Encinar JA, et al. Differential effects of IGF-1R small molecule tyrosine kinase inhibitors BMS-754807 and OSI-906 on human cancer cell lines. Cancers (Basel). 2020;12:3717.","journal-title":"Cancers (Basel)."},{"key":"1844_CR105","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.3390\/cancers16183175","volume":"16","author":"MS Hassan","year":"2024","unstructured":"Hassan MS, Johnson C, Ponna S, et al. Inhibition of insulin-like growth factor 1 receptor\/insulin receptor signaling by small-molecule inhibitor BMS-754807 leads to improved survival in experimental esophageal adenocarcinoma. Cancers (Basel). 2024;16:3175.","journal-title":"Cancers (Basel)."},{"key":"1844_CR106","first-page":"7000","volume":"15","author":"C Su","year":"2018","unstructured":"Su C, Wang W, Wang C. IGF-1-induced MMP-11 expression promotes the proliferation and invasion of gastric cancer cells through the JAK1\/STAT3 signaling pathway. Oncol Lett. 2018;15:7000\u20136.","journal-title":"Oncol Lett"},{"key":"1844_CR107","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/carcin\/bgy142","volume":"40","author":"YK Huang","year":"2019","unstructured":"Huang YK, Kang WM, Ma ZQ, et al. NUCKS1 promotes gastric cancer cell aggressiveness by upregulating IGF-1R and subsequently activating the PI3K\/Akt\/mTOR signaling pathway. Carcinogenesis. 2019;40:370\u20139.","journal-title":"Carcinogenesis"},{"key":"1844_CR108","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"1844_CR109","first-page":"1021","volume":"21","author":"G Jiang","year":"2020","unstructured":"Jiang G, Deng W, Liu Y, Wang C. General mechanism of JQ1 in inhibiting various types of cancer. Mol Med Rep. 2020;21:1021\u201334.","journal-title":"Mol Med Rep"},{"key":"1844_CR110","first-page":"491","volume":"73","author":"X Shi","year":"2018","unstructured":"Shi X, Liu C, Liu B, et al. JQ1: a novel potential therapeutic target. Pharmazie. 2018;73:491\u20133.","journal-title":"Pharmazie"},{"key":"1844_CR111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41389-020-0218-z","volume":"9","author":"S Zhou","year":"2020","unstructured":"Zhou S, Zhang S, Wang L, et al. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2\/NID1 signaling. Oncogenesis. 2020;9:33.","journal-title":"Oncogenesis"},{"key":"1844_CR112","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41419-017-0181-6","volume":"9","author":"X Dong","year":"2018","unstructured":"Dong X, Hu X, Chen J, Hu D, Chen LF. Brd4 regulates cellular senescence in gastric cancer cells via E2F\/miR-106b\/p21 axis. Cell Death Dis. 2018;9:203.","journal-title":"Cell Death Dis"},{"key":"1844_CR113","doi-asserted-by":"crossref","first-page":"43997","DOI":"10.18632\/oncotarget.9766","volume":"7","author":"RC Montenegro","year":"2016","unstructured":"Montenegro RC, Clark PG, Howarth A, et al. Bet inhibition as a new strategy for the treatment of gastric cancer. Oncotarget. 2016;7:43997\u20134012.","journal-title":"Oncotarget"},{"key":"1844_CR114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13046-023-02615-2","volume":"42","author":"M Feng","year":"2023","unstructured":"Feng M, Xu H, Zhou W, Pan Y. The BRD4 inhibitor JQ1 augments the antitumor efficacy of abemaciclib in preclinical models of gastric carcinoma. J Exp Clin Cancer Res. 2023;42:44.","journal-title":"J Exp Clin Cancer Res"},{"key":"1844_CR115","volume":"1878","author":"S Singh","year":"2023","unstructured":"Singh S, Sadhukhan S, Sonawane A. 20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight. Biochimica et Biophysica Acta (BBA). 2023;1878: 188967.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"1844_CR116","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","volume":"41","author":"BC Cho","year":"2023","unstructured":"Cho BC, Ahn MJ, Kang JH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol. 2023;41:4208\u201317.","journal-title":"J Clin Oncol"},{"key":"1844_CR117","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.3390\/ijms25105565","volume":"25","author":"AK Piper","year":"2024","unstructured":"Piper AK, Penney C, Holliday J, et al. EGFR and PI3K signalling pathways as promising targets on circulating tumour cells from patients with metastatic gastric adenocarcinoma. Int J Mol Sci. 2024;25:5565.","journal-title":"Int J Mol Sci"},{"key":"1844_CR118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122342","volume":"629","author":"A Jadidi","year":"2022","unstructured":"Jadidi A, Shokrgozar MA, Sardari S, Maadani AM. Gefitinib-loaded polydopamine-coated hollow mesoporous silica nanoparticle for gastric cancer application. Int J Pharm. 2022;629: 122342.","journal-title":"Int J Pharm"},{"key":"1844_CR119","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-3-642-54490-3_7","volume":"201","author":"M Nolting","year":"2014","unstructured":"Nolting M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2014;201:125\u201343.","journal-title":"Recent Results Cancer Res"},{"key":"1844_CR120","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume":"211","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Schneider-Merck T, Trepel M. Lapatinib. Recent Results Cancer Res. 2018;211:19\u201344.","journal-title":"Recent Results Cancer Res"},{"key":"1844_CR121","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","volume":"17","author":"DY Oh","year":"2020","unstructured":"Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"1844_CR122","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1186\/s12885-021-08283-9","volume":"21","author":"G Ning","year":"2021","unstructured":"Ning G, Zhu Q, Kang W, et al. A novel treatment strategy for lapatinib resistance in a subset of HER2-amplified gastric cancer. BMC Cancer. 2021;21:923.","journal-title":"BMC Cancer"},{"key":"1844_CR123","first-page":"998","volume":"42","author":"Y Yu","year":"2018","unstructured":"Yu Y, Yu X, Liu H, Song Q, Yang Y. Mir-494 inhibits cancer-initiating cell phenotypes and reverses resistance to lapatinib by downregulating FGFR2 in HER2-positive gastric cancer. Int J Mol Med. 2018;42:998\u20131007.","journal-title":"Int J Mol Med"},{"key":"1844_CR124","doi-asserted-by":"crossref","first-page":"660","DOI":"10.5483\/BMBRep.2018.51.12.259","volume":"51","author":"KS Park","year":"2018","unstructured":"Park KS, Hong YS, Choi J, et al. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells. BMB Rep. 2018;51:660\u20135.","journal-title":"BMB Rep"},{"key":"1844_CR125","first-page":"9933274","volume":"2021","author":"H Yi","year":"2021","unstructured":"Yi H, Li Z, Liu X, Dai S, Li S. Therapeutic mechanism of lapatinib combined with sulforaphane on gastric cancer. Evid Based Complement Alternat Med. 2021;2021:9933274.","journal-title":"Evid Based Complement Alternat Med"},{"key":"1844_CR126","doi-asserted-by":"crossref","first-page":"32995","DOI":"10.1039\/C9RA03926K","volume":"9","author":"MW Attwa","year":"2019","unstructured":"Attwa MW, Kadi AA. Sapitinib: reactive intermediates and bioactivation pathways characterized by LC-MS\/MS. RSC Adv. 2019;9:32995\u20133006.","journal-title":"RSC Adv"},{"key":"1844_CR127","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejca.2019.10.010","volume":"124","author":"A Thomas","year":"2020","unstructured":"Thomas A, Virdee PS, Eatock M, et al. Dual erb b inhibition in Oesophago-gastric cancer (DEBIOC): a phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. Eur J Cancer. 2020;124:131\u201341.","journal-title":"Eur J Cancer"},{"key":"1844_CR128","volume":"10","author":"HL Gao","year":"2020","unstructured":"Gao HL, Gupta P, Cui Q, et al. Sapitinib reverses anticancer drug resistance in colon cancer cells overexpressing the ABCB1 transporter. Front Oncol. 2020;10: 574861.","journal-title":"Front Oncol"},{"key":"1844_CR129","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/978-981-13-0593-1_5","volume":"1044","author":"X Liu","year":"2018","unstructured":"Liu X, Meng FL. Generation of genomic alteration from cytidine deamination. Adv Exp Med Biol. 2018;1044:49\u201364.","journal-title":"Adv Exp Med Biol"},{"key":"1844_CR130","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12964-023-01417-5","volume":"22","author":"S Zhang","year":"2024","unstructured":"Zhang S, Liu Y, Ma X, et al. Recent advances in the potential role of RNA N4-acetylcytidine in cancer progression. Cell Commun Signal. 2024;22:49.","journal-title":"Cell Commun Signal"},{"key":"1844_CR131","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217159","volume":"601","author":"W Ouyang","year":"2024","unstructured":"Ouyang W, Huang Z, Wan K, et al. RNA ac(4)c modification in cancer: unraveling multifaceted roles and promising therapeutic horizons. Cancer Lett. 2024;601: 217159.","journal-title":"Cancer Lett"},{"key":"1844_CR132","doi-asserted-by":"publisher","DOI":"10.3390\/ph17050639","author":"AO Egunlusi","year":"2024","unstructured":"Egunlusi AO, Joubert J. NMDA receptor antagonists: emerging insights into molecular mechanisms and clinical applications in neurological disorders. Pharmaceuticals (Basel). 2024. https:\/\/doi.org\/10.3390\/ph17050639.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1844_CR133","volume":"472","author":"MR Rafe","year":"2024","unstructured":"Rafe MR, Saha P, Bello ST. Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders. Behav Brain Res. 2024;472: 115173.","journal-title":"Behav Brain Res"},{"key":"1844_CR134","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/0008-5472.CAN-21-1017","volume":"81","author":"F Xu","year":"2021","unstructured":"Xu F, Tong M, Tong CSW, et al. A combinatorial CRISPR-Cas9 screen identifies Ifenprodil as an adjunct to Sorafenib for liver cancer treatment. Cancer Res. 2021;81:6219\u201332.","journal-title":"Cancer Res"},{"key":"1844_CR135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ebiom.2019.03.009","volume":"42","author":"B Turanli","year":"2019","unstructured":"Turanli B, Zhang C, Kim W, et al. Discovery of therapeutic agents for prostate cancer using genome-scale metabolic modeling and drug repositioning. EBioMedicine. 2019;42:386\u201396.","journal-title":"EBioMedicine"},{"key":"1844_CR136","first-page":"15","volume":"11","author":"WG North","year":"2019","unstructured":"North WG, Liu F, Dragnev KH, Demidenko E. Small-cell lung cancer growth inhibition: synergism between NMDA receptor blockade and chemotherapy. Clin Pharmacol. 2019;11:15\u201323.","journal-title":"Clin Pharmacol"},{"key":"1844_CR137","first-page":"79","volume":"9","author":"WG North","year":"2017","unstructured":"North WG, Liu F, Lin LZ, Tian R, Akerman B. NMDA receptors are important regulators of pancreatic cancer and are potential targets for treatment. Clin Pharmacol. 2017;9:79\u201386.","journal-title":"Clin Pharmacol"},{"key":"1844_CR138","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1158\/2767-9764.CRC-24-0093","volume":"4","author":"M Mizunuma","year":"2024","unstructured":"Mizunuma M, Redon CE, Saha LK, et al. Acetalax (Oxyphenisatin Acetate, NSC 59687) and bisacodyl cause oncosis in triple-negative breast cancer cell lines by poisoning the ion exchange membrane protein TRPM4. Cancer Res Commun. 2024;4:2101\u201311.","journal-title":"Cancer Res Commun"},{"key":"1844_CR139","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1158\/2767-9764.CRC-24-0435","volume":"5","author":"WC Reinhold","year":"2025","unstructured":"Reinhold WC, Marangoni E, Elloumi F, et al. Acetalax and bisacodyl for the treatment of triple-negative breast cancer: a combined molecular and preclinical study. Cancer Res Commun. 2025;5:375\u201388.","journal-title":"Cancer Res Commun"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01844-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01844-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01844-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:49:36Z","timestamp":1764917376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01844-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,31]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1844"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01844-3","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,31]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (1975, last revised in 2013), and national and institutional ethical standards. Ethical approval for this study was obtained from the institutional review board from Changzhou Cancer Hospital (2024(SR)NO.014).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent has been obtained from the patient(s) to publish this paper.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"309"}}